AU7750100A - Method for the treatment of obesity - Google Patents

Method for the treatment of obesity

Info

Publication number
AU7750100A
AU7750100A AU77501/00A AU7750100A AU7750100A AU 7750100 A AU7750100 A AU 7750100A AU 77501/00 A AU77501/00 A AU 77501/00A AU 7750100 A AU7750100 A AU 7750100A AU 7750100 A AU7750100 A AU 7750100A
Authority
AU
Australia
Prior art keywords
obesity
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU77501/00A
Inventor
Jessica E. Matthews
David Lee Musso
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9924275.2A external-priority patent/GB9924275D0/en
Priority claimed from GB0001861A external-priority patent/GB0001861D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AU7750100A publication Critical patent/AU7750100A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
AU77501/00A 1999-10-13 2000-10-03 Method for the treatment of obesity Abandoned AU7750100A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9924275.2A GB9924275D0 (en) 1999-10-13 1999-10-13 Method for the treatment of obesity
GB9924275 1999-10-13
GB0001861 2000-01-28
GB0001861A GB0001861D0 (en) 2000-01-28 2000-01-28 Method for the treatment of obesity
PCT/US2000/027252 WO2001026641A2 (en) 1999-10-13 2000-10-03 Morpholinol derivatives for the treatment of obesity

Publications (1)

Publication Number Publication Date
AU7750100A true AU7750100A (en) 2001-04-23

Family

ID=26243494

Family Applications (1)

Application Number Title Priority Date Filing Date
AU77501/00A Abandoned AU7750100A (en) 1999-10-13 2000-10-03 Method for the treatment of obesity

Country Status (6)

Country Link
EP (1) EP1220673A2 (en)
JP (1) JP2003511410A (en)
AR (1) AR026022A1 (en)
AU (1) AU7750100A (en)
PE (1) PE20010744A1 (en)
WO (1) WO2001026641A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003013649A2 (en) 2001-08-08 2003-02-20 Orton Kevin R Apparatus and method for electrically conductive weight reduction
EP2301537A1 (en) * 2002-05-17 2011-03-30 Duke University Zonisamide for the treatment of obesity
HUE034290T2 (en) 2003-04-29 2018-02-28 Orexigen Therapeutics Inc Compositions for affecting weight loss comprising an opioid antagonist and bupropion
CA2630624C (en) 2005-11-22 2013-08-06 Orexigen Therapeutics, Inc. Compositions and methods for increasing insulin sensitivity
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
AU2007319472B2 (en) 2006-11-09 2013-01-17 Nalpropion Pharmaceuticals Llc Methods Of Administering Weight Loss Medications
RU2010126828A (en) * 2007-12-05 2012-01-10 Астразенека Аб (Se) MORPHOLINE DERIVATIVES AS AN OBESITY MEANS
EP2303025A4 (en) 2008-05-30 2012-07-04 Orexigen Therapeutics Inc Methods for treating visceral fat conditions
CA2726646A1 (en) * 2008-06-04 2009-12-10 Astrazeneca Ab New compounds vii
US9248123B2 (en) 2010-01-11 2016-02-02 Orexigen Therapeutics, Inc. Methods of providing weight loss therapy in patients with major depression
PL3730132T3 (en) 2012-06-06 2022-10-10 Nalpropion Pharmaceuticals Llc Composition for use in a method of treating overweight and obesity in patients with high cardiovascular risk

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8924528D0 (en) * 1989-10-31 1989-12-20 Wellcome Found Heterocyclic pharmaceutical compounds,preparation and use
WO1998047513A1 (en) * 1997-04-24 1998-10-29 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating eating disorders
WO1999025355A1 (en) * 1997-11-14 1999-05-27 Glaxo Group Ltd. Method of treating addiction to nicotine products
AU755536B2 (en) * 1998-01-21 2002-12-12 Glaxo Group Limited Pharmaceutically active morpholinol
MA26693A1 (en) * 1998-09-28 2004-12-20 Glaxo Group Ltd COMPOSITIONS FOR ORAL ADMINISTRATION

Also Published As

Publication number Publication date
EP1220673A2 (en) 2002-07-10
PE20010744A1 (en) 2001-07-23
WO2001026641A2 (en) 2001-04-19
WO2001026641A3 (en) 2002-01-10
JP2003511410A (en) 2003-03-25
AR026022A1 (en) 2002-12-26

Similar Documents

Publication Publication Date Title
AU2935200A (en) Compounds for the treatment of obesity
HK1047284A1 (en) 2-amino-benzoxazinone derivatives for the treatment of obesity
AU6367099A (en) Improved process for water treatment
AU7085900A (en) Airway treatment apparatus
AU3246701A (en) Method and apparatus for the treatment of substrates
AU6855100A (en) Water treatment apparatus
ZA200108446B (en) Novel method of treatment.
AU7902400A (en) Method for the preparation of 5-carboxyphthalide
AU2001277534A1 (en) Method for locating compounds which are suitable for the treatment and/or prophylaxis of obesity
HUP0200738A3 (en) Method of the treatment of incontinence
AU7750100A (en) Method for the treatment of obesity
AU2002236781A1 (en) Treatment for snoring
AU2003233820A1 (en) Method for the treatment of starch
AU5547000A (en) Novel treatment
AU7363000A (en) Method for reducing the risk of cancer
AU4556800A (en) Novel treatment
AU7804000A (en) Fluid treatment apparatus
AU4598400A (en) Method of treatment
AU1130901A (en) Method for the preparation of 5-carboxyphthalide
AU2924400A (en) Plant treatment method
AU5174699A (en) Apparatus and method for the production of disinfectant
AU2382601A (en) Novel method of treatment
AU2000272704A1 (en) Use of compounds for the treatment of obesity
AU2289100A (en) Binding partners for 5-ht5-receptors for the treatment of migraine
GB9924275D0 (en) Method for the treatment of obesity

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase